📊 NDRA Key Takeaways
Is NDRA a Good Investment? Thesis Analysis
Pre-revenue medical device company with $7M annual net losses and only $762K cash, implying critical 2-3 month funding runway. Despite 39% YoY loss improvement, the company faces severe liquidity risk without imminent revenue generation or capital raise. Fundamental business model remains unproven in electromedical apparatus sector.
Why Buy NDRA? Key Strengths
- Zero long-term debt - no leverage risk
- Net losses improving 38.9% YoY - suggests operational progress
- Minimal capex requirements - asset-light development model
NDRA Investment Risks to Consider
- Critical cash position with ~2-3 months runway at current $5.2M burn rate
- Pre-revenue status with unvalidated commercialization pathway
- Severe negative profitability with -310.9% ROE and -182.4% ROA
- Imminent capital raise likely required, exposing shareholders to substantial dilution
- No demonstrated market traction or regulatory progress visibility
Key Metrics to Watch
- Monthly cash burn rate and remaining runway
- Clinical trial enrollment/regulatory milestone announcements
- Capital raise activity and dilution impact
- Revenue recognition or pre-revenue metrics (pilot programs, partnerships)
- Insider transaction patterns indicating confidence
NDRA Financial Metrics
💡 AI Analyst Insight
ENDRA Life Sciences Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
NDRA Profitability Ratios
NDRA vs Healthcare Sector
How ENDRA Life Sciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NDRA Overvalued or Undervalued?
Based on fundamental analysis, ENDRA Life Sciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NDRA Balance Sheet & Liquidity
NDRA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: ENDRA Life Sciences Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-56.94 indicates the company is currently unprofitable.
NDRA Growth Metrics (YoY)
NDRA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2019 | N/A | -$2.8M | N/A |
| Q2 2019 | N/A | -$1.8M | N/A |
| Q1 2019 | N/A | -$2.7M | N/A |
| Q3 2018 | N/A | -$908.9K | N/A |
| Q2 2018 | N/A | -$1.4M | N/A |
| Q1 2018 | N/A | -$741.6K | N/A |
| Q3 2017 | N/A | -$908.9K | N/A |
| Q2 2017 | $57.8K | -$729.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NDRA Capital Allocation
NDRA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for ENDRA Life Sciences Inc. (CIK: 0001681682)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NDRA
What is the AI rating for NDRA?
ENDRA Life Sciences Inc. (NDRA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NDRA's key strengths?
Claude: Zero long-term debt - no leverage risk. Net losses improving 38.9% YoY - suggests operational progress.
What are the risks of investing in NDRA?
Claude: Critical cash position with ~2-3 months runway at current $5.2M burn rate. Pre-revenue status with unvalidated commercialization pathway.
What is NDRA's revenue and growth?
ENDRA Life Sciences Inc. reported revenue of $0.0.
Does NDRA pay dividends?
ENDRA Life Sciences Inc. pays dividends, with $0.0M distributed to shareholders in the trailing twelve months.
Where can I find NDRA SEC filings?
Official SEC filings for ENDRA Life Sciences Inc. (CIK: 0001681682) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NDRA's EPS?
ENDRA Life Sciences Inc. has a diluted EPS of $-8.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NDRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ENDRA Life Sciences Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NDRA stock overvalued or undervalued?
Valuation metrics for NDRA: ROE of -310.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NDRA stock in 2026?
Our dual AI analysis gives ENDRA Life Sciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NDRA's free cash flow?
ENDRA Life Sciences Inc.'s operating cash flow is $-5.2M, with capital expenditures of $17.3K.
How does NDRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -310.9% (avg: 15%), current ratio 1.29 (avg: 2).